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ABSTRACT
 
The SARS-CoV-2, a newly identified β-coronavirus, is the causative agent of the third 
large-scale pandemic from the last two decades. The outbreak started in December 2019 
in Wuhan City, Hubei province in China. The patients presented clinical symptoms 
of dry cough, fever, dyspnea, and bilateral lung infiltrates on imaging. By February 
2020, The World Health Organization (WHO) named the disease as Coronavirus Disease 
2019 (COVID-19). The Coronavirus Study Group (CSG) of the International Committee 
on Taxonomy of Viruses (ICTV) recognized and designated this virus as severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 uses the same 
host receptor, angiotensin-converting enzyme 2 (ACE2), used by SARS-CoV to infect 
humans. One hypothesis of SARSCoV-2 origin indicates that it is likely that bats serve 
as reservoir hosts for SARSCoV-2, being the intermediate host not yet determined. The 
predominant route of transmission of SARS-CoV-2 is from human to human. As of 
May 10th 2020, the number of worldwide confirmed COVID-19 cases is over 4 million, 
while the number of global deaths is around 279.000 people. The United States of 
America (USA) has the highest number of COVID-19 cases with over 1.3 million cases 
followed by Spain, Italy, United Kingdom, Russia, France and Germany with over 
223.000, 218.000, 215.000, 209.000, 176.000, and 171.000 cases, respectively.
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INTRODUCTION
The coronaviruses (CoVs) are a family of 
enveloped positive-stranded RNA viruses broadly 
distributed among mammals and birds that cau-
se respiratory and intestinal infections in animals 
and humans, and in some cases neurologic illness 
or hepatitis (1, 2). The CoVs have been the cau-
sative agent of two large-scale pandemics in the 
past two decades: 1) Severe acute respiratory syn-
drome (SARS) in 2002 and 2003 in Guangdong 
province, China (3, 4); and 2) Middle East respira-
tory syndrome (MERS) in 2012 in Middle Eastern 
countries (5, 6). After these two pandemic events, 
several pieces of evidence suggested possible futu-
re disease outbreaks: 1) CoVs undergo genetic re-
combination (7), which may lead to new evolving 
genotypes; 2) the presence of a large reservoir of 
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SARS-related coronaviruses (SARSr-CoVs) in hor-
seshoe bats in China (8, 9); and 3) previous studies 
determined that some bat SARSr-CoVs have the 
potential to infect humans (2, 10-13).
 The SARS-CoV-2, previously known as 
the 2019-novel coronavirus 2019-nCoV (14) (Fi-
gure-1), is a newly identified β-coronavirus that 
caused an epidemic of acute respiratory syndro-
me in humans, which started in December 2019 in 
the context of a seafood market in Wuhan, China 
(14). Later, in February 2020, The World Health 
Organization (WHO) named the disease as corona-
virus disease 2019 (COVID-19). The COVID-19 has 
now progressed to be transmitted by human-to-
-human ‘contact’ and spread within few months 
not only throughout China but also worldwide, 
affecting over 4 million people and killing more 
than 279.000 of them in 187 countries as of May 
10th 2020 (15). Typical clinical symptoms of CO-
VID-19 patients are fever, dry cough, breathing 
difficulties, headache and pneumonia and in some 
cases gastrointestinal infection symptoms. 
GENERAL CHARACTERISTICS OF SARS-CoV-2
 1 - Classification
 The CoVs were previously classified ba-
sed on serologic (cross-) reactivity involving the 
structural protein spike (S) glycoprotein until the 
classification shifted to comparative sequence 
analysis of replicative proteins (16, 17). The SARS-
-CoV-2 has been reported as the seventh corona-
virus known to infect humans (14, 18). SARS-CoV, 
MERS-CoV and SARS-CoV-2, all β-CoVs, can 
cause severe respiratory disease in humans. The 
other four human CoVs,  two α-CoVs HCoV-NL63 
and HCoV-229E, and two β-CoVs HCoV-OC43 and 
HCoV-HKU1, cause mild respiratory symptoms (2, 
13, 14). The SARS-CoV-2 clusters with SARS-
-CoVs in trees of the species Severe acute respi-
ratory syndrome-related coronavirus and genus 
Betacoronavirus (14, 18, 19) (Figure-2). Based on 
phylogeny and taxonomy, the Coronavirus Study 
Group (CSG) of the ICTV  recognized this virus as 
a sister to severe acute respiratory syndrome coro-
naviruses (SARS-CoVs) of the species Severe acute 
respiratory syndrome-related coronavirus and de-
signated it as severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) (19). 
 2 - Structure and Mechanism
 The first complete SARS-CoV-2 virus ge-
nome has been reported to be 29.9 kilobases (Gen-
Bank accession number MN908947) (18), which 
consists of six major open-reading frames (ORFs) 
Figure 1 - Ultrastructural morphology exhibited by coronaviruses. 
E protein, small envelope (E) protein; M protein, matrix (M) protein; S protein, spike (S) glycoprotein (homotrimer). Adapted from “Centers for Disease Control and Prevention 
(CDC)/ Alissa Eckert, MS; Dan Higgins, MAMS”.
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Phylogenetic tree including 52 genomes. Red dots, SARS-CoV-2 coronaviruses from the COVID-19 epidemic; yellow dots, SARS-CoV coronaviruses from the 2002-
03 SARS outbreak; and blue dots, SARS-like coronaviruses. Adapted from “github.com/blab/sars-like-cov”; “Built with blab/sars-like-cov and maintained by Trevor 
Bedford and Emma Hodcroft”.
Figure 2- Phylogeny of SARS-like betacoronaviruses including novel coronavirus SARS-CoV-2.
that are common to CoVs, and a number of other 
accessory genes (14, 18). Four ORFs of SARS-
-CoV-2 genome encode four essential structural 
proteins: (1) spike (S) glycoprotein (S1 and S2 su-
bunits) that attaches to the host receptor through 
the receptor binding domain (RBD) (S1 subunit), 
determines the virus host range (S1 subunit), and 
mediates virus-cell membrane fusion (S2 subu-
nit); (2) matrix (M) protein that mediates nutrients 
transport across the transmembrane, bud release 
and envelope formation; (3) small envelope (E) 
protein; and (4) nucleocapsid (N) protein which 
interfere with the host innate immune response 
(20) (Figure-1). The spike glycoprotein from CoVs 
forms homotrimers protruding from the viral sur-
face and mediating the entry of the virus genome 
into the host cells (21). Therefore, it constitutes 
the main target of neutralizing antibodies after in-
fection and hence, the focus of vaccine designing 
(22). Two structural acquisition of SARS-CoV-2 
spike (S) glycoprotein have not been found in li-
neage B β-coronavirus: 1) a functional polybasic 
(furin) cleavage site at the junction between the 
S1/ S2 subunits which is cleaved during biogene-
sis; and 2) three adjacent predicted O-linked gly-
cans (22). Curiously, the acquisition of polybasic 
cleavage sites in the hemagglutinin protein from 
low-pathogenic avian influenza viruses turns 
them into highly pathogenic forms (23). The in-
troduction of the predicted O-linked glycans could 
build a ‘mucin-like domain’, like those found in 
Ebola and Marburg viruses, that shields select im-
munodominant epitopes on the SARS-CoV-2 spike 
protein (24). O-glycosylated ‘mucin-like domains’ 
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may physically hinder the interaction between 
virus-infected cells and immune cells (25). 
 The SARS-CoV-2 uses the same host re-
ceptor, angiotensin-converting enzyme 2 (ACE2), 
used by SARS-CoV to infect humans (14). ACE2 
is a metalloprotease expressed in the cells of the 
lung, intestine, liver, heart, vascular endothelium, 
testis and kidney (2). In addition, the SARS-CoV-2 
seems to have an RBD that binds with high affi-
nity to ACE2 from humans and other species with 
high receptor homology (26). Six amino acids pre-
sent in the RBD of the spike protein are essential 
for binding to host ACE2 receptors, and for esta-
blishing the host range of SARS-CoV-like viruses. 
Interestingly, five of these six amino acids differ 
between SARS-CoV-2 and SARS-CoV (26). 
 3 - Theories of SARS-CoV-2 Origins
 It has been reported that MERS-CoV ori-
ginated from bats, being dromedary camels the 
reservoir host triggering the spillover to humans 
(27). However, palm civets and racoon dogs have 
been indicated as an intermediate host for zoono-
tic transmission of SARS-CoV bridging bats and 
humans (28). In this sense, the intermediate host 
of SARS-CoV-2 remains unknown. Nevertheless, 
Ge et al. (9) proposed that some bat SARS-like co-
ronaviruses (SL-CoVs) may directly infect human 
cells without an intermediate host. They were able 
to isolate a live bat SL-CoV (bat SL-CoV-WIV1, 
Figure-2) from bat fecal samples, which shares 
99.9% sequence identity to Rs3367 (Figure-2), a 
bat coronavirus from Chinese horseshoe bats in 
Yunnan, China, and uses the ACE2 receptor from 
humans, civets and Chinese horseshoe bats for 
cell entry (9). Later in 2015, Menachery et al. (11) 
validated this hypothesis by synthetically produ-
cing an infectious recombinant virus from a bat 
coronavirus SHC014 (RsSHC014, Figure-2) that 
could efficiently replicate both in vitro in primary 
human airway cells, and in vivo in mouse lung. 
Thus, they emphasized the potential risk of SARS-
-CoV re-emergence from viruses currently circu-
lating in bat populations without the necessity of 
an intermediate host (11).
 Andersen et al. (29) have recently postula-
ted two hypotheses that could explain the origin 
of SARS-CoV-2: 1) Natural selection in an ani-
mal host before zoonotic transfer; and 2) Natural 
selection in humans following zoonotic transfer. 
Regarding the first hypothesis, it is likely that bats 
serve as reservoir hosts for SARSCoV-2 (30, 31), since 
the genome sequence of SARS-CoV-2 shares a 96.2% 
identity at the whole genome level with that of bat 
CoV RaTG13 (14) (phylogenetic proximity in the cla-
de SARS-CoV-2//bat/Yunnan/RaTG13/2013, Figu-
re-2). Nonetheless, Wu et al. (18) reported that bats 
were not available for selling in the seafood market, 
where the first COVID-19 cases appeared (18). They 
found that the SARS-CoV-2 virus strain designated 
as WHCV (GenBank accession number MN908947) 
shares a nucleotide identity of 89.1% with bat SARS-
-like CoV isolated from bat (Bat-SL-CoVZC45- Gen-
Bank accession number MG772933) that had been 
previously collected from Zhoushan City, Zhejiang 
province, China, between 2015 and 2017 (32) (bat_
SL_CoVZC45, Figure-2). Interestingly, the spike 
glycoprotein from some pangolin CoVs shows high 
similarity to SARS-CoV-2 in the RBD, which includes 
all six key RBD residues (33), supporting the existence 
of alternative intermediate host like pangolins, snakes 
and turtles (34), though not yet identified. This also 
indicates that all six key RBD residues may have been 
already present in the virus that jumped to humans 
(29). In terms of the second hypothesis, Andersen et 
al. (29) proposed that the genomic characteristics ac-
quired from the progenitor of SARS-CoV-2, which 
would prime a pandemic outbreak, have taken place 
initially in humans during an undetected human-to-
-human transmission. 
TRANSMISSION
 The common transmission routes of SARS-
-CoV-2 include: 1) Direct exposure with cough, snee-
ze and droplet inhalation within a range of about 1.8 
meters; and 2) Contact transmission through contact 
with oral, nasal, and eye mucous membranes (35). It 
has been also suggested that the SARS-CoV-2 trans-
mission is not only limited to the respiratory tract 
(36), the eye mucosa may provide the virus with the 
portal to enter the body (32). Similarly, saliva may 
also directly or indirectly transmit SARS-CoV-2 (37). 
This is especially important during dental procedures, 
since aerosols and droplets mixed with patient’s saliva 
and even contaminated blood with virus are genera-
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ted (38). In similar way, Wax et al. (39) suggested that 
SARS-CoV-2 may be airborne through aerosols for-
med during medical procedures (39). In this sense, 
indirect contact via contaminated surfaces is ano-
ther possible cause of infection. Interestingly, the 
presence of SARS-CoV-2 in fecal swabs (29%) and 
blood (1%) from infected individuals indicated the 
possibility of multiple transmission routes; howe-
ver, no individuals contained detectable viral RNA 
in their urine (40). Additionally, it has been repor-
ted that contact with asymptomatic patients may 
represent another form of virus transmission (41). 
In this aspect, an epidemiological model published 
at the beginning of the outbreak in China sugges-
ted that subclinical infections may have been the 
source of a majority of infections (42). 
 International actions have been taken to 
reduce the social viral transmission by imple-
menting “physical distancing” strategies, such as 
staying at least two meters apart from other peo-
ple, not gathering in groups, considering delivery 
services, using cloth face cover to protect mouth 
and nose when around others or when going out in 
public, working from home when possible, avoi-
ding the use of public transportation, implemen-
ting digital/distance learning. “Quarantine” has 
been employed to keep someone who might have 
been exposed to COVID-19 away from others, and 
“isolation” to separate sick people from healthy 
ones. Those actions have impacted on the viral 
transmission profile in those countries that follo-
wed the guidelines from the “Centers for Disease 
Control and Prevention” (CDC) (Figures 3A and B).
 
DISEASE PATHOPHYSIOLOGY AND THE IMMUNE 
RESPONSE
The clinical manifestations of COVID-19 ran-
ge from mild to severe compromise, with few cases 
showing a fatal course. The most common reported 
symptoms are fever, cough, myalgia or fatigue, follo-
wed by pneumonia, and dyspnea, whereas less com-
mon reported symptoms include headache, diarrhea, 
and hemoptysis (43). Patients with mild symptoms 
were reported to recover after one week while seve-
re cases experienced progressive respiratory failure 
due to alveolar damage, likely leading to death (43). 
Although the exact pathophysiological mechanisms 
underlying SARS-CoV-2 disease are not properly 
understood, genomic similarities to SARS-CoV may 
allow to infer the accompanying inflammatory res-
ponse as being involved in the development of severe 
pneumonia (44, 45) (Table-1). 
Histopathological observations of pulmonary 
lesions from SARS cases not only show nonspecific 
inflammatory responses such as edema and inflam-
matory cell infiltration but also a severe exfoliation 
of alveolar epithelial cells, alveolar septal widening, 
damage to alveolar septa, as well as alveolar space 
infiltration in a distinctly organized manner. SARS‐
CoV infection can cause pathological changes, dege-
neration, infiltration, and hyperplasia. Damage to the 
pulmonary interstitial arteriolar walls indicates that 
the inflammatory response plays an important role 
throughout the course of disease despite (or beyond) 
the pathogenic effect of Coronaviruses (46). 
Even though SARS-CoV-2 is less lethal than 
MERS-CoV, up to 10-20%, people over 60 years and 
those with underlying medical co-morbidities, are 
more likely to develop a severe disease characterized 
by interstitial pneumonia and acute respiratory dis-
tress syndrome (ARDS) or even septic shock. Likewi-
se, it is common to observe high levels of acute-phase 
reactants and features from the macrophage activa-
tion syndrome such as hyperferritinaemia, hepatic 
dysfunction and diffuse intravascular coagulation 
(44). Case definition guidelines consider symptoms 
like fever, decrease in lymphocytes and white blood 
cells, new pulmonary infiltrates on chest radiogra-
phy, and no improvement in symptoms after 3 days 
of antibiotics treatment (43). 
During a viral infection, the host mounts an 
immune response (IR) addressed to contain the in-
fection. Recent advances in the knowledge of the in-
nate IR against viruses point out that this type of IR 
inhibits virus replication, promotes virus clearance, 
induces tissue repair, while promoting a prolonged 
adaptive IR against the viruses. In most cases, pulmo-
nary and systemic inflammatory responses associa-
ted with coronavirus are mediated by innate immune 
mechanisms upon virus recognition. However, an 
exacerbated IR also plays an immunopathogenic role, 
accounting for pulmonary tissue damage, functional 
impairment, and reduced lung capacity (43). The da-
maged cells induce innate inflammation in the lungs, 
largely mediated by proinflammatory macrophages 
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Figure 3 - SARS-CoV-2 transmission. 
Number of cumulative cases per million of inhabitants: Both graphs (A and B) show the daily evolution of the number of detected cumulative cases of COVID-19 until 
50 days after the first reported case normalized to each country’s population. In the upper right boxes the absolute number of cases during the same time period is 
shown. (A) Transmission of SARS-CoV-2 in countries (Portugal, Germany, Peru, Italy, Spain, USA, France) which number of cases/million inhabitants is greater than 
500 (cumulative cases/ million inhabitants). (B) Transmission of SARS-CoV-2 in countries (China, Argentina, Colombia, Mexico, Venezuela, Uruguay, Brazil) which 
number of cases/million inhabitants is smaller than 500 (cumulative cases/ million inhabitants). The data used for the construction of the curves were obtained from 
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and granulocytes. Such lung inflammation further 
emerges as the main cause of life-threatening respi-
ratory disorders in severely ill patients (47) (Figure-4).
When a virus invades the host, the viral nu-
cleic acid is initially recognized by Pattern Recog-
nition Receptors, like Toll Like receptor 4 (TLR4) or 
Melanoma Differentiation Antigen 5 (MDA-5), that 
recognize S protein or nucleic acids, respectively. A 
signaling cascade is then activated to promote the 
synthesis of type I interferons (IFN-alpha and IFN-
-beta). Type I IFNs subsequently activate the downs-
tream JAK‐STAT signal pathway, promoting the ex-
pression of IFN‐stimulated gene(s). As host’s major 
antiviral molecules, IFNs limit virus spread, play a 
promoting role for macrophage phagocytosis of anti-
gens, as well as Natural Killer (NK) cells restriction of 
infected target cells and T/B cells. It follows, that blo-
cking the production of IFNs has a direct effect on the 
survival of the virus within the host (46) (Figure-4).
Cytokine deregulation was also thought to 
underlie ARDS development. Apparently, SARS-
-CoV2, induces abnormally low levels of antiviral 
cytokines, particularly type I interferons, which form 
part of the very early IR to viral infections (44). Such 
lack of an antiviral innate IR may favor a poorly con-
trolled viral replication with progressive increases in 
viral load and the accompanying pro inflammatory 
systemic response. This situation continues until the 
appearance of the adaptive IR, which brings viral re-
plication under control. Concerning SARS-CoV2, its 
clinical severity is related to the high viral load and 
the intense inflammatory response as evidenced by 
serum cytokine profiles and histopathology (2). 
Moving to antiviral adaptative IR, CD4+ T 
cells, and CD8+ T cells particularly play a significant 
antiviral role, with the former promoting the produc-
tion of virus‐specific antibodies by activating T‐de-
pendent B cells; and CD8+ T cytotoxic cells, killing 
viral infected cells. Of note, CD8+ T cells account for 
about 80% of total infiltrative inflammatory cells in 
the lung interstitium from SARS‐CoV‐ infected pa-
tients,  being involved in coronaviruses clearance of 
infected cells as well as immune injury (46). Addi-
tionally, T helper cells produce pro inflammatory 
cytokines via the NF‐kB signaling pathway. Cytokine 
dysregulation is of particular interest in patients with 
COVID-19, who have higher levels of inflammatory 
cytokines. However, what is more interesting is that, 
as seen during the SARS outbreak, some cytokines 
seem to be up-regulated, especially in patients with 
more severe disease. IL‐17 cytokines recruit mo-
nocytes and neutrophils to the site of infection whi-
ch in turn activate other downstream cytokine and 
chemokine cascades, such as IL‐1, IL‐6, IL‐8, IL‐21, 
TNF‐β, and MCP‐1 (44, 46). Some studies showed that 
the levels of inflammatory cytokines are high in the 
lungs of COVID-19 patients like TNF-α and IL-1. Be-
sides disease severity correlated with TNF-α, IL-6 and 
IL-10 levels (44) (Figure-4). 
On the other hand, a worth considering ques-
tion deals with the generation of immune memory 
to SARS-CoV-2. Considering the knowledge gathe-
red from another coronaviruses, in SARS convales-
cents patients, memory T cell responses are directed 
at SARS‐CoV structural proteins. These responses are 
found to last up to 11 years after infection. There is 
also evidence for an absence of cross‐reactivity of 
these CD8+T cell responses against the MERS‐CoV 
(46). 
In summarizing, the IR induced by SARS-
-CoV-2 infection is two phased. During the incuba-
tion period and non-severe stages, a specific adaptive 
immune response is required to eliminate the virus 
and to preclude disease progression to advanced 
Table 1- Summary of the symptoms recorded in 191 COVID-19 confirmed patients hospitalized in Jinyintan Hospital or Wuhan 
Pulmonary Hospital before January 31st, 2020 (45). (n= 191).
Fever (temperature 
>37.3°C)
Cough Sputum Myalgia Fatigue Diarrhoea Nausea or 
vomiting
180 (94%) 151 (79%) 44 (23%) 29 (15%) 44 (23%) 9 (5%) 7 (4%)
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Figure 4- Diagram of the immune response to infection with SARS-CoV-2.
The intracellular response of the infected macrophage is shown on the left side of the figure. As shown, both protein S and viral RNA will induce the production 
of pro-inflammatory cytokines as well as type 1 interferons. The main activation pathways are those that lead to nuclear translocation of NF-kB and IRF (Interferon 
Response Factors). On the right side are shown the cells of the innate as well as the adaptive immune response that are involved in antiviral immunity, with the 
mechanisms of cytotoxicity as well as those of humoral immunity being the most relevant. TLR4, Toll Like receptor 4; MDA-5, Melanoma Differentiation Antigen 5; 
IFN, Type I Interferon; NK cells, Natural Killer Cells; IRF3 and 7, Interferon Response Factors; TNF-β, Tumor necrosis factor-β; MCP-1, Monocyte Chemoattractant 
Protein-1; Th17, T-helper 17 cells.
disease. Therefore, strategies to boost immune res-
ponses (anti-sera or pegylated IFNα) at this stage are 
certainly welcome. However, when a protective IR is 
impaired, the virus will propagate favoring a subs-
tantial destruction of affected tissues, especially in 
tissues that have high ACE2 expression (47). In turn, 
damaged cells will fuel innate-mediated inflamma-
tion in the lungs largely mediated by pro inflamma-
tory macrophages and granulocytes. As stated, lung 
inflammation therefore emerges as a critical factor 
for life-threatening respiratory disorders at the severe 
stage (47).
THE DIAGNOSIS OF COVID-19 PATIENTS
 Intensive testing of suspected cases to iden-
tify COVID-19 infected people is critical to avoid the 
further spread of infection. The in vitro diagnostic as-
says based on viral nucleic acid detection using real-
-time reverse transcriptase polymerase chain reaction 
(RT-PCR) (~80% sensitivity) remain the standard of 
reference (48-51) (Table-2). The assay duration has 
been shortened from 2-3 hours to 45 minutes; ho-
wever, it is unable to detect the SARS-CoV-2 in early 
stages of viral infection, giving false negatives in pe-
ople infected up to two weeks after symptom onset. 
Possible reasons for the low detection efficiency 
could be low patient viral load or improper cli-
nical sampling. In this sense, chest radiography 
and computed tomography (CT) (~65% sensitivity) 
represent a complementary diagnostic tool that 
allows physicians to effectively make a diagno-
sis, reaching in many cases a higher sensitivity 
(~91%) by combining both tools (52). 
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Table 2- Summary of in vitro diagnostic assays based on SARS-CoV-2 viral nucleic detection
Assay type/
name











-Nose and throat 
swabs
N.R. -E gene: 3.2 RNA 
copies/reaction 
(95% detection)





by  Corman et al. 
(49)





-Sputum > 1 hour <10 RNA copies/
reaction

















































-Nose and throat 
swabs











5 min N.R. ABBOTT, USA
Real-time RT-PCR = real-time reverse transcriptase polymerase chain reaction; N.R = not reported; UK = United Kingdom
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 Other in vitro diagnostic assays, such as 
several serological immunoassays (rapid lateral 
flow immunoassay (LFIA) tests, automated che-
miluminescence immunoassay (CLIA), and ma-
nual ELISA) detect SARS-CoV-2 viral proteins 
and antibodies like IgM and IgG, in the serum or 
plasma. The detection of IgM ranges from 10 to 
30 days after SARS-CoV-2 infection; however, 
that of IgG from 20 days onwards (48) (Table-3). 
Additionally, other routine blood exami-
nations are used to monitor the status of CO-
VID-19 infection, such as liver and kidney func-
tion, myocardial markers, myoglobin, ferritin, 
erythrocyte sedimentation rate, C-reactive pro-
tein (CRP), procalcitonin (PCT), lactate, D-dimer, 
complete blood count, coagulation profile, urine 
routine test, creatine kinase, lactate dehydroge-
nase, electrolytes and inflammatory factors (in-
terleukin (IL)-6, IL-10, TNF-α). Monitoring CRP 
and PCT levels help to distinguish whether there 
was bacterial infection in the lung. D-dimer in-
fers the risk for blood clotting (thrombosis) and/
or thrombotic embolism. It has been observed 
that in most severe COVID-19 patients, the D-
-dimer level is significantly increased showing 
frequent clotting disorders and microthrombotic 
formations. Quantifying inflammatory factors, 
especially IL-6, may help to preliminarily eva-
luate the immune status of patients in terms of 
the cytokine release syndrome (45).
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15 min N.R. Chembio Diagnostics, USA
* = automated chemiluminescence immunoassay (CLIA); ** = rapid lateral flow immunoassay (LFIA).
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